A Pathway, Not A Shortcut: 505(b)(2) NDAs Have Longer Reviews Than NMEs

US FDA's argument that its review resources favor novelty/medical advances could be buttressed by Tufts Center for the Study of Drug Development analysis of (less novel) approvals using the streamlined 505(b)(2) NDA pathway.